Zynerba Pharmaceuticals, Inc. (ZYNE)
| Market Cap | 41.83M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.84M |
| Shares Out | 43.62M |
| EPS (ttm) | -0.96 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 290,596 |
| Open | 1.010 |
| Previous Close | 0.988 |
| Day's Range | 0.909 - 1.010 |
| 52-Week Range | 0.836 - 6.070 |
| Beta | 2.11 |
| Analysts | Buy |
| Price Target | 7.09 (+639.3%) |
| Earnings Date | May 18, 2022 |
About ZYNE
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is h...
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ZYNE stock is "Buy." The 12-month stock price forecast is 7.09, which is an increase of 639.31% from the latest price.
News
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
– Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 –
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragil...
– Data support the long-term safety and effectiveness of Zygel –
Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting
DEVON, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...
Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragil...
DEVON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neu...
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting
DEVON, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...
Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
DEVON, Pa., April 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...
Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit
DEVON, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...
Zynerba (ZYNE) Loses 29.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zynerba (ZYNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear...
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) –
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syn...
Provides 10-year market exclusivity in EU upon regulatory approval Provides 10-year market exclusivity in EU upon regulatory approval
Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Topline data from Phase 2 INSPIRE trial expected mid-year 2022 Topline data from Phase 2 INSPIRE trial expected mid-year 2022
Zynerba Pharmaceuticals Names New CLO & Corporate Secretary
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal off...
Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal O...
DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...
Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has decided not to advance Zygel against developmental and epileptic encephalopathies (DEE). The decision was in line with the feedback from the FDA, which ind...
Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE
– Company plans to focus development of Zygel™ in FXS, ASD and 22q –
Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium
DEVON, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...
Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™
DEVON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...
Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights
– Initiated RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X Syndrome (FXS); topline results expected second-half 2023 –
Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October
DEVON, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...
Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare ...
DEVON, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...
Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conferen...
DEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare ne...
Top Penny Stocks To Buy The Dip According To Analysts In September
Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare n...
Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
Trial will evaluate the efficacy and safety of Zygel in children and adolescents with Fragile X Syndrome
Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with autism spectrum disorder (ASD) over a longer-term, 38-week treatment per...